BETHESDA, MD (PRWEB) September 19, 2014
Kyrgyzstan has one of the highest rates of tuberculosis in Central Asia. To reduce the burden of tuberculosis (TB) and address the issue of drug-resistant TB in the Kyrgyz Republic, Abt Associates has been awarded the U.S. Agency for International Development (USAID)-funded Kyrgyzstan TB Program under a five-year cooperative agreement with total funding of $12.7 million. The project will also support universal and equitable access to high-quality TB services for vulnerable populations through a strengthened and sustainable health system.
“Tuberculosis is a significant threat to public health in the Kyrgyz Republic. Abt’s goal is always to achieve a sustainable health impact and bring our unmatched expertise to help solve this pressing health challenge,” said Diana R. Silimperi, M.D., Vice President of International Health at Abt Associates.
The Kyrgyzstan TB Program expands Abt’s robust infectious disease portfolio and builds on more than 20 years of work by Abt in the former Soviet countries of Central Asia to strengthen health systems and institutions, support health financing reform and quality service delivery, and promote more efficient, accessible, patient-centered health care. The country-based project team will be led initially by Dr. Roza Adilbekova, one of the leading TB experts in the region with extensive experience designing, managing, and implementing TB programmatic activities in Central Asia.
About Abt Associates
Abt Associates is a mission-driven, global leader in research and program implementation in the fields of health, social and environmental policy, and international development. Known for its rigorous approach to solving complex challenges, Abt Associates is regularly ranked as one of the top 20 global research firms and one of the top 40 international development innovators. The company has multiple offices in the U.S. and program offices in more than 40 countries. http://www.abtassociates.com.